Discontinuation rates trended higher than with semaglutide or tirzepatide, and TRIUMPH-4 flagged a dysesthesia signal (abnormal skin sensations) in up to roughly 21% of participants on 12 mg versus about 0.7% on placebo
For now, orforglipron remains an investigational medication and can only be accessed through clinical trials
Significant weight loss outcomes in Phase 2 (up to 24.2% at 12mg over 48 weeks) were recorded at higher doses
Perimenopause most often begins between ages 40 and 44, but many women start noticing symptoms as early as their mid-to-late Menopause Patches Menopause can bring uncomfortable symptoms like hot flashes, night sweats, poor sleep, mood changes, and brain fog
Track your body composition (not just scale weight) monthly to verify that muscle loss isn't occurringif you're eating in a deficit and training hard, creatine helps tip the scale toward muscle retention